Darbepoetin is a long-acting analog of erythropoietin, the hormone that signals the bone marrow to manufacture red blood cells. In extremely low birth weight infants, who are born before they can mount a robust red cell response and who lose blood through frequent laboratory testing, randomized trials have shown that darbepoetin raises hematocrits and can reduce or even eliminate the need for red blood cell transfusions. That is a major clinical win, because transfusions in preterm infants have been linked in multiple studies to complications including retinopathy of prematurity and bronchopulmonary dysplasia. But erythropoiesis-stimulating agents come with a catch: they only work if the marrow has an adequate supply of iron to load into the hemoglobin of every new cell it produces. Without sufficient iron, the drug drives the production of red cells that are small, pale, and poorly equipped to carry oxygen.

The problem facing neonatologists is that assessing iron status in a premature infant is surprisingly difficult. Serum ferritin, the most commonly used storage iron marker in adults, is highly variable in neonates born before 29 weeks of gestation and does not correlate well with functional iron availability, as earlier work by the same group demonstrated. Inflammation, transfusions, and the normal physiology of early infancy all muddy the interpretation. What clinicians really want to know is not how much iron is stored somewhere in the body, but whether the erythron, the collective machinery of red cell production, is actually getting enough iron at this moment to build hemoglobin properly. That functional question is where reticulocyte-based measurements come in.

Reticulocytes are the immature red blood cells released by the bone marrow, and because they circulate for only a day or two before maturing, they offer a real-time snapshot of erythropoietic activity. One established metric, RET-He, measures the hemoglobin content of reticulocytes in picograms. A falling RET-He signals that newly produced cells are being under-filled with hemoglobin, a classic hallmark of iron-limited erythropoiesis. The Utah team tracked RET-He alongside reticulocyte counts in both darbepoetin-treated infants and placebo recipients, and the numbers they recovered are striking. Among placebo recipients, RET-He fell over the first week from 33.6 plus or minus 0.5 picograms to 27.4 plus or minus 0.2 picograms, a statistically significant decline with a p value below 0.001. Infants receiving darbepoetin fell even further, with the difference between groups reaching p below 0.0001.

At first glance, that pattern looks alarming: the drug seems to be driving infants into deeper iron deficiency. But the researchers identified something more nuanced, a reciprocal relationship between rising reticulocyte counts and falling RET-He. As darbepoetin accelerates the marrow’s output, the pool of available iron is distributed across a rapidly expanding population of new cells, so each reticulocyte carries less hemoglobin even if total iron delivery is adequate for the infant’s needs. This dilutional effect means that a low RET-He during stimulated erythropoiesis cannot be read the same way it would be in a stable patient. A single threshold value, applied without context, risks mislabeling infants as iron deficient when their iron supply is actually keeping pace with an unprecedented demand, or conversely missing true deficiency hidden behind a vigorous marrow response.

To resolve that ambiguity, the team turned to two novel erythrocyte parameters generated by modern hematology analyzers: Micro-R, which quantifies microcytosis, the proportion of red cells that are abnormally small, and HYPO-He, which quantifies hypochromia, the proportion of cells with reduced hemoglobin concentration. Unlike RET-He, which reflects the most recent cohort of cells leaving the marrow, these metrics survey the entire circulating red cell population and capture the structural fingerprints of iron-limited cell production over a longer window. Reference intervals for Micro-R and HYPO-He in newborn infants had previously been established by members of the same group using the refineR algorithm, giving the investigators a validated framework for interpreting the values they observed during darbepoetin therapy.

The central finding of the study emerged when the two measurement families were read together. Among darbepoetin recipients whose RET-He dropped below 25 picograms, a level that would traditionally raise concern for iron deficiency, the majority, 83 percent, had Micro-R and HYPO-He measurements indicating that they were in fact iron sufficient. In other words, most of the infants flagged by the conventional marker were not truly iron limited; their low reticulocyte hemoglobin content reflected the physiology of accelerated erythropoiesis rather than a genuine shortfall in iron supply. Only a minority showed the concordant microcytosis and hypochromia that would confirm real iron-restricted red cell production. This discordance is precisely why the authors advocate using traditional and novel red cell markers in combination rather than in isolation.

The clinical implications extend beyond the neonatal unit’s fascination with laboratory parameters. Iron deficiency in early life is not a benign laboratory curiosity; iron is essential for brain development, and studies have linked iron deficiency in extremely low birth weight infants to adverse neurodevelopmental outcomes at two years of age. Overtreating with iron, on the other hand, carries its own risks, including oxidative stress and potential toxicity in infants who cannot yet regulate absorption. A monitoring strategy that reliably distinguishes true iron deficiency from the benign dilution of hemoglobin across a surging reticulocyte population would allow clinicians to target supplementation precisely, giving iron to the infants who need it and avoiding unnecessary exposure in those who do not. As restrictive transfusion guidelines become more common and erythropoiesis-stimulating agents play a growing role in keeping preterm infants transfusion-free, the stakes of getting iron assessment right only increase.

The study was conducted as a retrospective, deidentified records review approved by the Intermountain Health Institutional Review Board with a waiver of informed consent, and it was performed in accordance with federal human subjects protections. The authors, including Natalie Bishara, Timothy M. Bahr, Anne Woodbury, Robert D. Christensen, and Robin K. Ohls, report no competing interests, and both the statistical code and the underlying data are available on reasonable request. Because the analysis drew on existing trial and clinical datasets rather than a prospective interventional design, the findings will need prospective validation before they change bedside practice, and the precise algorithm for integrating RET-He, Micro-R, and HYPO-He into a clinical decision rule remains to be defined.

Even so, the conceptual shift the paper describes is likely to resonate widely. For decades, iron sufficiency has been inferred from snapshots of storage or from single thresholds applied to dynamic systems. The Utah work shows that during accelerated erythropoiesis, the very condition in which accurate iron assessment matters most, the traditional markers move in ways that can mislead, and that the structural signatures written into circulating red cells by iron-limited production offer a corrective lens. If follow-up studies confirm the approach, neonatologists may soon monitor their tiniest patients not with a single number but with a coordinated panel that reads both the tempo of red cell production and the quality of the cells being produced, ensuring that every dose of darbepoetin is matched by the iron those infants need to build oxygen-carrying blood and to protect their developing brains.

Subject of Research: Iron sufficiency assessment in premature infants treated with darbepoetin using conventional and novel erythrocyte metrics

Article Title: Assessment of iron sufficiency in premature infants treated with darbepoetin using conventional and novel erythrocyte metrics

Article References: Bishara, N., Bahr, T. M., Woodbury, A., Christensen, R. D., & Ohls, R. K. (2026). Assessment of iron sufficiency in premature infants treated with darbepoetin using conventional and novel erythrocyte metrics. Journal of Perinatology. https://doi.org/10.1038/s41372-026-02889-2

Image Credits: AI Generated

DOI: 10.1038/s41372-026-02889-2

Keywords: darbepoetin, premature infants, iron deficiency, RET-He, Micro-R, HYPO-He, reticulocytes, erythropoiesis, neonatology, anemia, transfusion avoidance, extremely low birth weight